Viatris Inc. (VTRS)
| Market Cap | 13.72B |
| Revenue (ttm) | 15.43B |
| Net Income (ttm) | 54.70M |
| Shares Out | 1.19B |
| EPS (ttm) | 0.05 |
| PE Ratio | 231.00 |
| Forward PE | 4.07 |
| Dividend | $0.48 (4.16%) |
| Ex-Dividend Date | Mar 8, 2024 |
| Volume | 7,193,318 |
| Open | 11.34 |
| Previous Close | 11.36 |
| Day's Range | 11.25 - 11.58 |
| 52-Week Range | 8.74 - 13.62 |
| Beta | 1.15 |
| Analysts | Sell |
| Price Target | 11.00 (-4.76%) |
| Earnings Date | May 9, 2024 |
About VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent... [Read more]
Full Company ProfileFinancial Performance
In 2023, Viatris's revenue was $15.43 billion, a decrease of -5.14% compared to the previous year's $16.26 billion. Earnings were $54.70 million, a decrease of -97.37%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VTRS stock is "Sell." The 12-month stock price forecast is $11.0, which is a decrease of -4.76% from the latest price.
News
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
PITTSBURGH , April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Ch...
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
PITTSBURGH , April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will b...
UK watchdog says Theramex-Viatris deal raises competition concerns
Britain's competition watchdog said Theramex's purchase of European rights to two of Viatris' women's healthcare products ranges could lead to higher prices and lesser options for hormone replacement ...
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to...
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for...
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
PITTSBURGH , March 27, 2024 /PRNewswire/ -- At a meeting with the investment community today, Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will outline how it is continuing to evolve its ...
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 18, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VT...
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
NEW YORK , March 11, 2024 /PRNewswire/ -- IN THE COURT OF COMMON PLEAS OF ALLEGHENY COUNTY, PENNSYLVANIA RAJESH PATEL, Individually and on Behalf of All Others Similarly Situated, ...
US FDA declines to approve Viatris's injection for multiple sclerosis
The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.
Viatris forecasts strong 2024 sales on higher demand for branded drugs
Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma.
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
PITTSBURGH , Feb. 28, 2024 /PRNewswire/ -- Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1] Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7...
Idorsia and Viatris enter into a significant global research and development collaboration
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand Collab...
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
PITTSBURGH , Feb. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full-year 2023 financial results Wednesday, Feb. 28, 2024, before the open of the U.S. financ...
Charts turn bullish on health-care stocks as sector takes early lead in 2024
Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h...
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
PITTSBURGH , Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference i...
Drugmaker Viatris appoints Theodora Mistras as CFO
Global healthcare company Viatris on Friday appointed Theodora Mistras as its chief financial officer, effective March 1.
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
Company thanks Sanjeev Narula for his role in the successful execution of Viatris' Phase 1 strategy; Narula will support a smooth CFO transition prior to his departure on March 1, 2024 PITTSBURGH , De...
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
Board of Directors Elects Melina Higgins New Chair PITTSBURGH , Dec. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced that at its 2023 Annual Meeting of Sha...
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
BENGALURU, India, Nov. 30, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars...
Why the Cheapest Stock in the S&P 500 Is No Bargain
Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has been falling ever since the deal closed.
Viatris to Participate in the Jefferies London Healthcare Conference
PITTSBURGH , Nov. 14, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in Londo...
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Top-line results from Phase III study in China demonstrate the efficacy and safety profile of YUPELRI in patients with COPD PITTSBURGH and DUBLIN , Nov. 13, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: ...
Viatris core profit beats on generic drugs strength
Viatris beat Wall Street estimates for third-quarter core profit on Tuesday, helped by strength in its generic drug portfolio, sending its shares up about 2% in extended trading.